Point72 Asset Management
TBPH icon

Point72 Asset Management’s Theravance Biopharma TBPH Stock Holding History

Point72 Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,500
Closed -$196K – 4480
2025
Q4 		$196K Buy
+10,500
New +$174K ﹤0.01% 3642

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's TBPH Position: Q3 2025 in Review

Point72 Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2025, closing a stake of 12,692 shares — an estimated $140K sold.

Point72 Asset Management first reported a position in TBPH in Q4 2016 and held it in 7 quarters. The position peaked at $25.2M in Q3 2021. 162 funds tracked by Wall St. Rank hold TBPH as of Q3 2025.

  • Point72 Asset Management reported no remaining Theravance Biopharma position as of Q3 2025 after selling out during the quarter.
  • Point72 Asset Management sold 12,692 Theravance Biopharma shares in Q3 2025, an estimated $140K.
  • Point72 Asset Management first reported a position in Theravance Biopharma in Q4 2016 and held it in 7 quarters.
  • Point72 Asset Management's Theravance Biopharma position peaked at $25.2M in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2025.

Based on Point72 Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.